SCHEMBL1266650

SCHEMBL1266650

COc1ccc2ncc3c(c2n1)C(CC(NCC=Cc1cc(F)ccc1F)[C@H]1CCNC1)CO3

nearest known ligand 0.39

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 6/20 0.34
SLC2A1 P11166 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1267512 0.97 KCNH2 (0.34) KCNH2SLC2A1
SCHEMBL1267437 0.78 KCNH2 (0.47) KCNH2
SCHEMBL1266540 0.78 SLC2A1 (0.45) KCNH2SLC2A1
SCHEMBL1266536 0.78 SLC2A1 (0.45) KCNH2SLC2A1
SCHEMBL1266537 0.78 SLC2A1 (0.45) KCNH2SLC2A1
SCHEMBL1266428 0.76 SLC2A1 (0.44) KCNH2SLC2A1
SCHEMBL1266427 0.76 SLC2A1 (0.44) KCNH2SLC2A1
SCHEMBL1266425 0.76 SLC2A1 (0.44) KCNH2SLC2A1
SCHEMBL1266748 0.75 KCNH2 (0.47) KCNH2
SCHEMBL1267509 0.75 SLC2A1 (0.40) KCNH2SLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110039836-A1 TRICYCLIC ANTIBIOTICS ACTELION PHARMACEUTICALS LTD. (CH) 2011-02-17 US claimed
US-8012961-B2 Tricyclic antibiotics ACTELION PHARMACEUTICAL LTD. (CH) 2011-09-06 US disclosed
US-20110039836-A1 TRICYCLIC ANTIBIOTICS ACTELION PHARMACEUTICALS LTD. (CH) 2011-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039836-A1 TRICYCLIC ANTIBIOTICS OPRM1, UBE2D3, METTL3 KCNH2 924/4885SLC2A1 4373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.